Companies in the Healthcare Sector Report Financial Results, and Scheduled Conference calls - Research Report on OXiGENE, BioTelemetry, Abiomed, Emeritus, and Genomic Health

NEW YORK, November 11, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting OXiGENE, Inc. (NASDAQ: OXGN), BioTelemetry Inc. (NASDAQ: BEAT), Abiomed Inc. (NASDAQ: ABMD), Emeritus Corp. (NYSE: ESC), and Genomic Health Inc. (NASDAQ: GHDX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

OXiGENE, Inc. Research Report

On November 4, 2013, OXiGENE, Inc. (OXiGENE) announced that it will report its Q3 2013 financial results on Tuesday, November 12, 2013. The Company informed that it will host a conference call and its webcast on the same day at 4:30 p.m. ET (1:30 p.m. PT). OXIGENE stated that the live audio webcast and archive of the same will be available under the Investors section of the Company website. The Full Research Report on OXiGENE, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/f6ec_OXGN]

--

BioTelemetry Inc. Research Report

On November 5, 2013, BioTelemetry Inc. (BioTelemetry) released its Q3 2013 financial results. Revenue was up by 17.9% YoY to $31.9 million during the quarter. The Company reported adjusted net income of $339,000 in Q3 2013, versus adjusted net loss of $1.9 million in Q3 2012. Net loss during the quarter stood at $3 million compared to $3.1 million in Q3 2012. Commenting on the results, Joseph Capper, President and CEO of the Company stated, "We are extremely pleased that our first quarter as BioTelemetry, Inc. was a successful one. We posted an 18% increase in revenue to $32 million which produced $3.6 million of adjusted EBITDA, up $3.3 million over the third quarter of 2012. The quarter was filled with many accomplishments as we established our new corporate structure, increased our patient services volume, posted solid financials, signed a contract to service Kaiser Permanente, received FDA approval of CardioKey and improved our balance sheet. The business clearly has excellent momentum and we expect to continue to fuel growth through the disciplined execution of our strategic plan." The Full Research Report on BioTelemetry Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/d815_BEAT]

--

Abiomed Inc. Research Report

On November 6, 2013, Abiomed Inc. (Abiomed) released its Q2 FY 2014 financial results (period ended September 30, 2013) with revenues of $44.3 million, up by 18.5% YoY. Net income arrived at $1.1 million or $0.03 per diluted share in Q2 FY 2014, compared to $5.5 million or $0.13 per diluted share in Q2 FY 2013. Michael R. Minogue, Chairman, President and CEO of the Company, stated, "Abiomed achieved many new quarterly records on Impella utilization, including most overall patients, most prophylactic patients and most emergent patients. We are on track to transform into a PMA and PMDA company while setting new records in patient utilization and completing enrollment in our Impella RP study." For full-year FY 2014, the Company anticipates revenue to be in the range of $180 million to $185 million. The Full Research Report on Abiomed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/ea34_ABMD]

--

Emeritus Corp. Research Report

On November 5, 2013, Emeritus Corp. (Emeritus) released its Q3 2013 financial results. Total operating revenues were up by 29.0% YoY to $491.7 million during the quarter. Net loss attributable to the Company's common stock holders stood at $27.8 million or $0.59 per diluted share in Q3 2013, compared to $16.3 million or $0.36 per diluted share in Q3 2012. Granger Cobb, the Company's President and CEO stated, "Occupancy improved sequentially from the second quarter of this year, and our leading indicators are stable and improving. We continue to expect a roughly 20% improvement in cash from facility operations for the full year 2013. During the quarter we welcomed 39 new communities into the Emeritus family; we also continue to generate solid growth in home healthcare services, which we have expanded to now include Arizona and Texas. Our performance is a tribute to our 31,000 extremely dedicated Emeritus employees who remain resolutely focused on providing a fulfilling customer experience for our residents and peace of mind to their families." The Full Research Report on Emeritus Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

 [http://www.analystscorner.com/r/full_research_report/d611_ESC]

--

Genomic Health Inc. Research Report

On November 5, 2013, Genomic Health Inc. (Genomic Health) released its Q3 2013 financial results. Total revenues were up by 12.5% YoY to $66 million during the quarter. Net income was $488,000 or $0.02 per diluted share in Q3 2013, compared to $3.7 million or $0.11 per diluted share in Q3 2012. Kim Popovits, Chairman of the Board, CEO and President of the Company stated, "Our strong third quarter performance, including 13 percent year-over-year growth in product revenue, was driven by double digit test volume growth in all areas of our business. Success in the quarter was also highlighted by increased adoption of our prostate cancer test and NICE's recommendation of Oncotype DX as the only test to help clinicians decide whether to prescribe chemotherapy in patients with early-stage, hormone receptor-positive, invasive breast cancer." The Full Research Report on Genomic Health Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/db58_GHDX]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED